KalVista Pharmaceuticals/$KALV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About KalVista Pharmaceuticals
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Ticker
$KALV
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
270
Website
KALV Metrics
BasicAdvanced
$726M
-
-$3.69
-0.04
-
Price and volume
Market cap
$726M
Beta
-0.04
52-week high
$16.32
52-week low
$7.30
Average daily volume
1.7M
Financial strength
Current ratio
5.351
Quick ratio
5.22
Long term debt to equity
115.537
Total debt to equity
117.61
Interest coverage (TTM)
-32.50%
Profitability
EBITDA (TTM)
-187.054
Effective tax rate (TTM)
-1.88%
Management effectiveness
Return on assets (TTM)
-48.34%
Return on equity (TTM)
-121.50%
Valuation
Price to book
7.61
Price to tangible book (TTM)
7.61
Price to free cash flow (TTM)
-4.706
Free cash flow yield (TTM)
-21.25%
Free cash flow per share (TTM)
-309.82%
Growth
Earnings per share change (TTM)
7.32%
3-year earnings per share growth (CAGR)
3.17%
10-year earnings per share growth (CAGR)
-20.12%
What the Analysts think about KALV
Analyst ratings (Buy, Hold, Sell) for KalVista Pharmaceuticals stock.
Bulls say / Bears say
The FDA's approval of KalVista's Ekterly as the first oral on-demand treatment for hereditary angioedema (HAE) positions the company as a leader in this niche market, potentially capturing significant market share. (reuters.com)
Analysts estimate peak U.S. sales of Ekterly at around $250 million, indicating strong revenue potential due to early launch, premium pricing, and rapid adoption. (reuters.com)
KalVista's licensing agreement with Pendopharm to commercialize sebetralstat in Canada expands its market reach, potentially increasing revenue streams. (businesswire.com)
The FDA's extended review of sebetralstat due to heavy workload and limited resources could delay market entry, affecting revenue timelines. (reuters.com)
KalVista's recent $55 million underwritten offering and $5 million private placement may lead to shareholder dilution, potentially impacting stock value. (businesswire.com)
Insider selling, such as the Chief Development Officer's sale of $19,218 in stock, might signal concerns about the company's future performance. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
KALV Financial Performance
Revenues and expenses
KALV Earnings Performance
Company profitability
KALV News
AllArticlesVideos
KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks
Business Wire·3 days ago
KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
Business Wire·2 weeks ago
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for KalVista Pharmaceuticals stock?
KalVista Pharmaceuticals (KALV) has a market cap of $726M as of July 28, 2025.
What is the P/E ratio for KalVista Pharmaceuticals stock?
The price to earnings (P/E) ratio for KalVista Pharmaceuticals (KALV) stock is 0 as of July 28, 2025.
Does KalVista Pharmaceuticals stock pay dividends?
No, KalVista Pharmaceuticals (KALV) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next KalVista Pharmaceuticals dividend payment date?
KalVista Pharmaceuticals (KALV) stock does not pay dividends to its shareholders.
What is the beta indicator for KalVista Pharmaceuticals?
KalVista Pharmaceuticals (KALV) has a beta rating of -0.04. This means that it has an inverse relation to market volatility.